| Literature DB >> 22929008 |
Alireza Valizadeh1, Haleh Mikaeili, Mohammad Samiei, Samad Mussa Farkhani, Nosratalah Zarghami, Mohammad Kouhi, Abolfazl Akbarzadeh, Soodabeh Davaran.
Abstract
This review introduces quantum dots (QDs) and explores their properties, synthesis, applications, delivery systems in biology, and their toxicity. QDs are one of the first nanotechnologies to be integrated with the biological sciences and are widely anticipated to eventually find application in a number of commercial consumer and clinical products. They exhibit unique luminescence characteristics and electronic properties such as wide and continuous absorption spectra, narrow emission spectra, and high light stability. The application of QDs, as a new technology for biosystems, has been typically studied on mammalian cells. Due to the small structures of QDs, some physical properties such as optical and electron transport characteristics are quite different from those of the bulk materials.Entities:
Year: 2012 PMID: 22929008 PMCID: PMC3463453 DOI: 10.1186/1556-276X-7-480
Source DB: PubMed Journal: Nanoscale Res Lett ISSN: 1556-276X Impact factor: 4.703
Figure 1Live HeLa cells growing on a glass coverslip. Labeled with QD-avidin for GM1 (in red) and Hoechst 3342 for nuclear staining (in blue) [46].
Figure 2HeLa cells labeled with the avidin-conjugated yellow-emitting QDs.[47]. (A) Image of cells immediately after the unbound QDs were removed in which labeling is restricted to the cell surface. (B) Image of a cell that was allowed to grow for 2 h after washing out of unbound QDs.
Figure 3Imaging of rough JM83 cells. Left imaging is red QD, and right imaging is green QD. Scale bar is 2 μM [49].
Figure 4Image was obtained with 363-nm excitation and × 40 oil 1.3 numerical aperture objective.
Figure 5Qualitative FISH detection of HER2 gene-amplified SK-BR-3 breast cancer cells. With (A) streptavidin-conjugated Qdot605 and (B) FITC, respectively [67].
Figure 6Double fluorescence staining to visualize the localization of M-cadherin (in red) and nuclei (in blue). Arrows indicate that M-cadherin-positive satellite cells were located within the intact soleus muscle in situ[72].
Figure 7Imaging of roots from plants exposed to QD suspension in HS + HA. For (A) 1 and (B) 7 days [74].HS, Hoagland's solution; HA, one of the important groups of organic acids.
Some of the infectious diseases and QDs used to distinguish them
| Tripp et al. [ | RSV | Antibody anti-F protein conjugated to QDs(CdTe) | |
| Agrawal et al. [ | Individual molecules of genes, proteins, and virus particles | QD-antibody color-coded NP probes and two-color co-localization imaging | |
| Bentzen et al. [ | RSV | Streptavidin-coated QDs conjugated to antibody anti-F and antibody anti-G | |
| Dwarakanath et al. [ | Antibody-QD and DNA aptamer-QD | ||
| | | | |
| | | | |
| Goldman et al. [ | Choleratoxin, ricin, shinga-like toxin1 and staphylococcal enterotoxin B | Antibody-QD (CdSe/Zns) | |
| Zhao et al. [ | Food-borne pathogenic | | QDanti- |
| Hahn et al. [ | Single cells of | | Streptavidin-coated QDs conjugated to antibody |
| Mukhopadhyay et al. [ | Detect | | Mannose-conjugated QDs |
| Edgar et al. [ | Streptavidin-coated QDs conjugated to phage | ||
| | | | |
| Zhu et al. [ | | QD-conjugated antibodies | |
| | | | |
| Klostranec et al. [ | Biomarkers of the most globally prevalent blood-borne infectious diseases (i.e., hepatitis B, hepatitis C, and HIV) with low sample volume | | QD-antibody |
| Gazouli et al. [ | Specific DNA sequences combining QDs with magnetic beads [ | ||
| Hahn et al. [ | Individual pathogenic | | Streptavidin-coated Qdots labeled by antibody selectively targeted pathogenic |
| Su and Li [ | Streptavidin-coated QDs conjugated to anti- | ||
| Yang and Li [ | QDs with different sizes conjugated to anti- | ||
| | | | |
| The bead-cell complexes reacted with QD-antibody conjugates to form bead-cell-QD complexes |
Other clinical therapeutic applications.
Figure 8Using QD conjugated with antibody for labeling of neurons and glia. (A) Labeled β-tubulin in primary cortical neurons. (B) Labeled glial fibrillary acidic protein in primary cortical astrocytes. (C) Labeled for β-tubulin in PC12 cells [106].
Applications of QDs in labeling neurons and glia cells
| Dahan et al. [ | QD-GlyR | Target neurons to investigate a specific neurophysiological process(QDs to track individual glycine receptors and analyze their lateral dynamics in the neuronal membrane) |
| Pathak et al. [ | Antibody-conjugated quantum dots | Performed the specific labeling of neurons and glia cells |
| Vu et al. [ | Tagged nerve growth factor (βNGF) to QDs | Investigate the QD nanostructure's potential to assess the neurite outgrowth |
| Sundara Rajan et al. [ | QD-anti-TrkA-TrkA receptor with transport by GFP | Immobilized QDs were conjugated with NGF, activate Trk receptors, and initiate neuronal differentiation in PC12 cells. |
| Howarth et al. [ | Tagged cell surface proteins with a specific peptide (acceptor protein) that can be directly biotinylated as a target for streptavidin-conjugated quantum dots | Specifically label and track AMPA receptors on cultured hippocampal neurons |
| Prasad et al. [ | Thioglycolic acid (TGA)-stabilized CdTe QDs | Performed imaging of PC12 cells |
Figure 9Confocal laser scanning fluorescence microscopyimages of cells labeled with CHPNH(15)-QD nanoparticle. (A) TIG-3 cells, (B) MRC-5 cells, (C) MCF-7 cells, and (D) YKG-1 cells [48].
QD delivery systems
| Jia et al. [ | Multiwalled carbon nanotube (MWNT) delivery system | MWNTs are containing antisense oligodeoxynucleotides and CdTe QDs via electrostatically layer-by-layer assembling. |
| Chen et al. [ | Tat peptide-mediated delivery system | QDs conjugated to the cell-penetrating peptide derived from the human immunodeficiency virus-1 transactivator protein |
| Lagerholm et al. [ | Peptide delivery system | Nine residue biotinylated l-arginine peptide is used to enhance delivery of streptavidin-conjugated QDs into mammalian cells. |
| Bagalkot et al. [ | A10 RNA aptamer | Functionalizes the surface of QD with the A10 RNA aptamer, which recognizes the extracellular domain of the prostate specific membrane antigen |
| Bakalova et al. [ | Silica-shelled quantum dots | Based on silica-shelled single QD micelles with incorporated paramagnetic substances [tris(2,2,6,6-tetramethyl-3,5-heptanedionate)/gadolinium] into the micelle and/or silica coat |
| Yum et al. [ | Nanoscale mechanochemical method | Using a membrane-penetrating nanoneedle |
| Yuan et al. [ | Chitosan (N-acetylglucosamine) tumor-targeted drug delivery | QDs encapsulated with chitosan |
| Hasegawa et al. [ | Nanogel-QD hybrid | Nanogels of CHPNH 2 with 15 amino groups per 100 glucose units and QDs that were conjugated with protein A molecules were mixed. |
| Dixit et al. [ | Viral vectors | QDs encapsulation in viral capsids |
| Zhang and Liu [ | Nonviral vectors | Cappingthe surface of ZnO QD with poly(2-(dimethylamino) ethyl methacrylate) |
| Jablonski et al. [ | Cationic peptide and a hydrophobic counterion | Quantum dots have been delivered to the cytosol of living cells using a combination of a cationic peptide, polyarginine, and a hydrophobic counterion, pyrenebutyrate. |
| Qi and Gau [ | QD-amphipol nanocomplex | Advantages include cytoplasm delivery and endosome escape. |
| Gao et al. [ | Polymeric delivery system | The structural design involves encapsulating QDs with an ABC triblock copolymer and linking this amphiphilic polymer. |
| Duan and Nie [ | Polymeric delivery system | QDs were encapsulated by PEI-g-PEG. |
More details for toxicity of QDs (modified from[163])
| CdSe/ZnS-SSA | EL-4 cells | 1 × 106 cells/well | 0.1 to 0.4 mg/mL | 0 to 24 h | Cytotoxic: 0.1 mg/mL altered cell growth; most cells nonviable at 0.4 mg/mL | Hoshino et al. 2004a |
| CdSe/ZnS-SSA | EL-4 cells | 200-μL cell suspension injected (iv) into the mice | 0.1 mg/mL QDs per 5 × 107 cells | 2 h to 7 days | No toxicity in mice | Hoshino et al. 2004a ( |
| CdSe/ZnS conjugates: NH2, OH, OH/COOH, H2/OH, MUA, COOH | WTK1 cells | 5 × 104 cells/mL | 1 to 2 μM | 12 h | 2-μM QD-COOH-induced DNA damage at 2 h | Hoshino et al. 2004b |
| CdSe/ZnS-MUA | Vero, HeLa, and primary human hepatocytes | 100-μL QDs/3 × 104 cells | 0 to 0.4 mg/mL | 24 h | Cytotoxic: 0.2 mg/mL, Vero; 0.1 mg/mL, HeLa; 0.1 mg/mL, hepatocytes | Shiohara et al. 2004 |
| CdTe | Rat pheochromocytoma cells, murine, microglial cells | 1 × 105 cells/cm2 | 0.01 to 100 μg/mL | 2 to 24 h | 10 μg/mL cytotoxic | Lovric et al. 2005 |
| CdSe-MAA, TOPO QDs | Primary rat hepatocytes | | 62.5-1,000 μg/mL | 1 to 8 h | Cytotoxic: 62.5 μg/mL cytotoxic under oxidative/photolytic conditions | Derfus 2004 |
| No toxicity on addition of ZnS cap | ||||||
| QD micelles: CdSe/ZnS QDs in (PEG-PE) and phosphatydilcholine | 5 × 109 QDs/cell(approximately 0.23 pmol/cell) | 1.5 to 3 nL of 2.3-μM QDs injected, approximately 2.1 × 109 to 4.2 × 109 injected QDs/cell | Days | 5 × 109 QDs/cell: cell abnormalities, altered viability and motility | Dubertret et al. 2002 | |
| No toxicity at 2 × 109 QDs/cell | ||||||
| CdSe/ZnS amp-QDs and mPEG QDs [ | Mice | 200-μL tail vein injection | Injections, approximately 180-nM QD, approximately20-pmol QD/g animal weight | 15-min cell incubations, 1 to 133 days | No signs of localized necrosis at the sites of deposition | Ballou et al. 2004 |
| CdSe/ZnS-DHLA | | 400 to 600 nM | 45 to 60 min | No effects on cell growth | Jaiswal et al. 2003 | |
| Avidin-conjugated CdSe/ZnS QDs | HeLa cells | | 0.5 to 1.0 μM | 15 min | No effect on cell growth and development | Jaiswal et al. 2003 |
| CdSe/ZnS-amphiphilic micelle | Mice | Tail vein injection | 60-μM QD/g animal weight, 1-μM and 20-nM final QD concentration | Not given | Mice showed no noticeable ill effects after imaging | Larson et al. 2003 |
| CdSe/ZnS-DHLA QDs | Mice, B16F10 cells | 5 × 104 B16F10 cells with 10-μL QDs (approximately 10 pmol), tail vein (iv) injection | 100 μL of B16F10 cells used for tail vein injection, approximately 2 × 105 to 4 × 105 cells injected | 4- to 6-h cell incubation, mice sacrificed at 1 to 6 h | No toxicity observed in cells or mice | Voura et al. 2004 |
| CdSe/ZnS-MUA QDs; QD-SSA complexes [ | Vero cells | 0.4 mg/mL | 0.24 mg/mL | 2 h | 0.4-mg/mL MUA/SSA-QD complexes did not affect viability of Vero cells | Hanaki et al. 2003 |
| CdSe/ZnS | HeLa cells | 1 × 106 cells | 10-pmol QDs/1 × 105 cells (approximately 10 nM) | 10 days (cell culture) | 10-nM QD had minimal impact on cell survival | Chen and Gerion 2004 |
| CdTe aqQDs | HEK293 cells | 1 × 105 cells | 300 or 600 nM | 3 days | Nearly completely inhibited cell growth even from the very beginning | Nan Chen et al. 2012 |
| CdTe-gelatinized/nongelatinized | PC12 cells | 1 × 105 cells/cm2 | 1 to 100 nM | 72 h | At 1 nM,did not initiate any detrimental effects; at 100 nM, resulted in the death of all cells | Babu R Prasad et al. 2010 |
| CdTe, CdTe/CdS, CdTe/CdS/ZnS | K562 and HEK293T human cell lines | 1 × 105 cells | 0.2 to 3.0 μM | 0 to 48 h | Cells treated with CdTe and CdTe/CdS QDs were mostly nonviable by 48 h (for all concentrations tested). | Su et al. 2009 |
| CdSe/ZnS-PEG (EviTag T1 490 QD) | Caco-2 (human colon carcinoma) cell line | 106 cells/ml, 0.2 ml/well | 0.84 to 105 μM | 0 to 24 h | Commercially available QD demonstrated low cytotoxicity but induced cell detachment. | Wang et al. 2008 |
| CdSe | Primary rat hippocampal neuron cells in culture | 104to 105 cells/ml | 1, 10, and 20nM | 24 h | 1-nM QD for 24 h showed no decrease in cell viability; in contrast, cells treated with 10- and 20-nM QD for 24 h showed decreases in cell viability on the order of 20 and 30%. | Tang et al., 2008 |